The following analysts currently issue reports on Shield Therapeutics:

Company Analyst
FinnCap Mark Brewer
Peel Hunt Dr Miles Dixon
Edison Soo Romanoff / Pooya Hemami
Hardman & Co Dr Martin Hall
Capital Network / Proactive Investors Dr John Savin

All of finnCap, Edison, Hardman & Co and Capital Network’s research on their corporate clients are free to view via the following links:

finnCap – There is a simple registration process for all non-institutional users and their corporate research is readily available

Hardman & Co

Capital Network/ Proactive Investors

Any opinions estimates or forecasts regarding the Company’s performance made by such analysts are theirs alone and do not represent opinions, forecasts or predictions of the Company or its Management. You should, therefore, not place undue reliance on the content of any such analyst report or statement.

Any reports issued may have become out of date following publication and should be read accordingly.

Focus on increasing US market access

Shield Therapeutics’ (STX) value stems from Accrufer’s US market opportunity as the company seeks to maximise returns through self-commercialisation. Recent progress on payer coverage and prescription uplift bodes well ...

Operating results eclipsed by financing difficulties

Shield Therapeutics reported FY21 results in line with market expectations, recording revenue of £1.5m, including a maiden £0.1m contribution from the United States after the July 2021 US launch of Accrufer. ...

2021 focus on Accrufer

Shield Therapeutics (STX) successfully launched its key asset, Accrufer (oral ferric maltol for iron deficiency), in the US market on 1 July, in line with previous guidance. The US commercialisation of ...

Greg Madison succeeds Tim Watts as CEO

Shield Therapeutics (STX) has announced the appointment of a new chief executive officer (CEO), Greg Madison, with effect from 1 June 2021. Greg is a seasoned CEO with previous experience of the ...

2021 all eyes on Accrufer US launch

Shield Therapeutics’ (STX) FY20 results reported total revenue of £10.4m reflecting an $11.4m (£9.7m) upfront payment received from ASK Pharm (Feraccru out-licensing deal that covers China) and £0.7m from royalties ...

Accrufer coming to America

Shield Therapeutics (STX) has placed c 83m shares at a deep discount (30.0p/share) to the market price, resulting in a gross raise of £25m. The funds will be utilised ...

Beefing up for the US opportunity

Shield Therapeutics’ (STX’s) shares fell sharply in December 2020 on the announcement that a US partnering deal would not be completed in 2020 and that the company is considering launching Accrufer ...

Close but no cigar

Shield Therapeutics (STX) has announced it is broadening its strategy for commercialising Accrufer in the US (oral therapy for iron deficiency, approved by the FDA in July 2019) and no longer ...

US partner next major inflection point

Shield Therapeutics’ (STX’s) interim results highlight the progress made year to date. Re-analysis of the Feraccru/Accrufer AEGIS-H2H data show it is a credible alternative to IV iron ...

AEGIS-H2H update – non-inferiority at 24 weeks

Shield Therapeutics (STX) has announced a technical update to findings from the AEGIS-H2H post-marketing study. The re-analysis demonstrates that Feraccru/Accrufer is a credible alternative to IV iron therapy ...

All eyes on a US partnering deal

Shield Therapeutics (STX) has reported FY19 results; total revenue of £0.7m reflects royalties on Feraccru sales from European partner Norgine. 2019 achievements include FDA approval of STX’s key asset for ...

Next step a US partnering deal

Shield Therapeutics (STX) has provided an updated trading statement ahead of FY19 results, expected at the end of May. In its January trading update, STX had guided to FY19 revenues ...

Tim Watts succeeds Carl Sterritt as CEO

Shield Therapeutics (STX) has announced that founder Carl Sterritt has resigned from his role as CEO with mutual agreement from its main shareholders. Tim Watts has been appointed as CEO ...

AEGIS-2 update

Shield Therapeutics (STX) has announced a technical update to findings from the AEGIS-H2H post-marketing study, which evaluated Feraccru/Accrufer versus IV iron. The update does not affect any of ...

2019 a landmark year

Today’s 2019 business and trading update highlights a landmark year for Shield Therapeutics. Feraccru/Accrufer (oral ferric maltol) is making inroads in Europe, with sales volumes growing 67% through commercialisation ...

Feraccru out-licensed in China

Shield Therapeutics has kick-started 2020 by securing an out-licensing deal in China for its primary asset, Feraccru/Accrufer. The exclusive deal with China-based Beijing Aosaikang Pharmaceutical (ASK Pharm) covers China, Hong ...

The land of opportunity awaits Accrufer

Shield Therapeutics’ interim results highlight a momentous year to date, with the FDA approval of primary asset Feraccru/Accrufer, for the treatment of iron deficiency (ID) in adults with ...

FDA approval attained, sales execution now key

Shield Therapeutics’ primary asset, Feraccru, has been approved by the FDA for the treatment of iron deficiency in patients with any underlying cause – the broadest possible label. It ...

Executive interview

Shield Therapeutics is a UK-based, speciality pharmaceutical company with a primary focus on commercialising its drug Feraccru, which is approved in Europe for the treatment of iron deficiency, with or ...

Next step US Feraccru approval

Shield Therapeutics reported FY18 results in line with our expectations. Total revenue of £11.9m included the £11.0m upfront payment from European partner Norgine. Operating expenses were substantially reduced ...

Feraccru performs again in a Phase III study

Shield Therapeutics has announced positive top-line data from a Phase IIIb study (AEGIS-H2H) for Feraccru, a CHMP-approved oral formulation of iron positioned for the treatment of iron deficiency (ID) ...

Fortified for growth

Shield Therapeutics is focused on the development and commercialisation of Feraccru, a CHMP-approved oral formulation of iron positioned for the treatment of iron deficiency (ID) with or without anaemia. In 2018, ...